It turns out that these receptors are present in many parts of the body, says Katherine Tuttle, a clinical professor of nephrology at the University of Washington School of Medicine.
After an average of three and a half years, the semaglutide group had a 24 percent lower likelihood of having a major kidney disease event-such as needing dialysis or a kidney transplant.
But Tuttle has her own theory for how semaglutide is protecting the kidney: by shutting down inflammation.
In a UK trial of 200 people with mild Alzheimer's disease, an older GLP-1 drug called liraglutide appeared to slow shrinking of the parts of the brain.
Collection
[
|
...
]